Home:
PCU2|2002: Judd
W Moul, MD: Select publications
Select publications
Iversen P et al. Bicalutamide monotherapy compared with
castration in patients with nonmetastatic locally advanced prostate
cancer: 6.3 years of followup. J Urol 2000;164(5):1579-82.
No abstract available.
Iversen P et al. Efficacy and tolerability of bicalutamide
in early non-metastatic prostate cancer: results of trial SPCG-6.
J Urol 2002;167(4 suppl):155. No abstract available.
Iversen P et al. Is the efficacy of hormonal therapy affected
by lymph node status? New data from the bicalutamide EPC program.
J Urol 2002;167(4Suppl):174. No abstract available.
Moul JW. Prostate specific antigen only progression of
prostate cancer. J Urol 2000;163(6):1632-42. Abstract
Moul JW. Rising PSA after local therapy failure: Immediate
vs deferred treatment. Oncology (Huntingt) 1999;13(7):985-90,
993; discussion 993-5, 999. Abstract
Moul J et al. Assessment of biochemical disease free survival
(DFS) in patients with hormonal therapy (HT) started for PSA-only
recurrence following radical prostatectomy. J Urol 2002;167(4Suppl):174.
No abstract available.
Moul JW et al. Predicting risk of prostate specific antigen
recurrence after radical prostatectomy with the Center for Prostate
Disease Research and Cancer of the Prostate Strategic Urologic Research
Endeavor databases. J Urol 2001;166(4):1322-7. Abstract
Pound CR et al. Natural history of progression after PSA
elevation following radical prostatectomy. JAMA 1999;281(17):1591-7.
Abstract
Sieber PR et al. Bone mineral density is maintained during
bicalutamide ('Casodex') treatment. Proc ASCO 2002;Abstract
783.
Siegel T et al. The development of erectile dysfunction
in men treated for prostate cancer. J Urol 2001;165(2):430-5.
Abstract
Smith CV et al. Prostate cancer in men age 50 years or
younger: A review of the Department of Defense Center for Prostate
Disease Research multicenter prostate cancer database.
J Urol 2000;164(6):1964-7. Abstract
Wirth M et al. Bicalutamide ("Casodex”) 150
mg as immediate or adjuvant therapy in 8113 men with localized or
locally advanced prostate cancer. Proc ASCO 2001;Abstract
705.
Wirth M et al. Bicalutamide (Casodex) 150 mg as immediate
therapy in patients with localized or locally advanced prostate
cancer significantly reduces the risk of disease progression.
Urol 2001;58:146-51. Abstract
Wirth MP et al. Efficacy of bicalutamide in early, non-metastatic
prostate cancer by initial disease stage and grade. J Urol
2002;167(4Suppl):345.No abstract available.
|
